Dr. Feng Tian
My Social Links

Dr. Feng Tian

Post-doctoral Fellow
China Academy of Chinese Medical Sciences, China

Highest Degree
Ph.D. in Clinical and Post-Marketing Methodology from China Academy of Chinese Medical Sciences, China

Share this Profile

Area of Interest:

Clinical Methodology
Post-Marketing Methodology

Research Publications in Numbers


Selected Publications

  1. Xie, Y.M., X. Liao and F. Tian, 2013. Translation and introduction of the guide on methodological standards in pharmacoepidemiology. China J. Chinese Materia Med., 38: 2949-2957.
  2. Xie, Y.M. and F. Tian, 2013. Regulations and guidelines should be strengthened urgently for Re-evaluation on Post-marketing medicines in China. Chinese J. Integrative Med., 19: 483-487.
    CrossRef  |  
  3. Xie, Y.M. and F. Tian, 2013. Interpretation on the guideline on good pharmacovigilance practices for the European Union. China J. Chinese Materia Medica, 38: 2963-2968.
  4. Li, Y., Y. Qin, Y. Xie, F. Tian, 2013. Grouped penalization estimation of the osteoporosis data in the traditional Chinese medicine. J. Applied Stat., 40: 699-711.
    CrossRef  |  Direct Link  |  
  5. Zhou, X.H., S.L. Li, F. Tian, B.J. Cai and Y.M. Xie et al., 2012. Building a disease risk model of osteoporosis based on traditional Chinese medicine symptoms and western medicine risk factors. Stat. Med., 31: 643-652.
    CrossRef  |  Direct Link  |  
  6. Zhou, X.H., B. Chen, Y.M. Xie, F. Tian, H. Liu and X. Liang, 2012. Variable selection using the optimal ROC curve: An application to a traditional Chinese medicine study on osteoporosis disease. Stat. Med., 31: 628-635.
    CrossRef  |  
  7. Yang, W., D.H. Yi, Y.M. Xie and F. Tian, 2012. Statistical identification of syndromes feature and structure of disease of western medicine based on general latent structure model. Chinese J. Integrative Med., 18: 850-861.
    Direct Link  |  
  8. Xie, Y., J. Li, Q. Cui, W. Lv and D. Yi et al., 2012. Analysis on risk factors of postmenopausal women with High-risk of osteoporosis based on multinomial logit model. World Sci. Technol.-Modern. Traditional Chinese Med., 14: 1835-1840.
    Direct Link  |  
  9. Xie, Y., B. Cai, F. Tian, D. Yi and Z. Yu et al., 2012. Establishment of a discriminant model for 40-65 years old postmenopausal osteoporosis women based on generalized partial linear model. Chinese J. Health Stat., 29: 837-839.
    Direct Link  |  
  10. Tian, F., Y.M. Xie, D.H. Yl, K. Yu, S. Kang, J.P. Li and Q.R. Cui, 2012. Reliability and validity analysis on risk factor and syndrome questionnaire of postmenopausal osteoporosis in 40-65 years' old women. Chinese J. Basic Med. Traditional Chinese Med., 18: 609-611.
    Direct Link  |  
  11. Tian, F., Y. Xie, S. Li, D. Yi and K. Yu et al., 2012. A screening tool for community high risk population with postmenopausal osteoporosis based on TCM theory. J. Traditional Chinese Med., 53: 1012-1015.
    Direct Link  |  
  12. Tian, F., J. Du, Y.M. Xie, Y. Pei and H. Liu et al., 2012. Reliability analysis of 40-65 years old women osteoporosis risk factors and TCM syndromes questionnaire based on generalizability theory. China J. Traditional Chinese Med. Pharmacy, 27: 193-195.
    Direct Link  |  
  13. Liao, X., Y.M. Xie, F. Tian and H. Shen, 2012. Overview of design, implementation and analysis of comparative effectiveness research China. J. Chinese Materia Medica, 38: 930-936.
  14. Xie, Y., Y. Wang, F. Tian and Y. Wang, 2011. Basic requirements on post-marketing clinical Re-evaluation of chinese medicine and phase IV clinical trials. China J. Chinese Materia Med., 36: 2764-2767.
    Direct Link  |  
  15. Xie, Y., W. Yang, F. Tian, D.H. Yi and K. Yu et al., 2011. Latent tree model analysis on TCM syndrome factors of primary osteoporosis among 40-65 years old women. Chinese J. Basic Med. Traditional Chinese Med., 17: 731-734.
  16. Tian, F., Y. Fu and Y. Xie, 2011. Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine. China J. Chinese Materia Med., 36: 1097-1102.
    PubMed  |  
  17. Tian, F. and Y. Xie, 2011. Research on postmenopausal osteoporosis related risk factors, prediction models and screening tools. Chinese J. Osteoporosis, 17: 166-171.
  18. Xie, Y., P. Mao and F. Tian, 2010. Prospect of real world study application in Post-marketing clinical reevaluation of Chinese medicine. Traditional Chinese Drug Res. Clin. Pharmacol., 21: 324-327.
  19. Xie, Y. and F. Tian, 2010. Translation and introduction of European Union's pharmacovigilance system of medicinal products for human use. Chinese Traditional Patent Med., 32: 119-122.
  20. Xie, Y. and F. Tian, 2010. A discussion of key issues on Post-marketing reevaluation of Chinese medicine. China J. Chinese Materia Med., 35: 1494-1497.
  21. Tian, F. and Y.M. Xie, 2010. Real-world study: A potential new approach to effectiveness evaluation of traditional Chinese medicine interventions. J. Chinese Integrative Med., 8: 301-306.
    CrossRef  |  PubMed  |  
  22. Tian, F. and Y. Xie, 2010. Thought and suggestions on development of stroke rehabilitation. Modern J. Integrated Traditional Chin. Western Med., 19: 1483-1486.
  23. Xie, Y. and F. Tian, 2009. Review on DRGs related researches. Chinese J. Inform. Traditional Chinese Med., 16: 119-121.
  24. Tian, F. and Y. Xie, 2009. The research of DRGs-PPS in our country. Chinese Health Econ., 28: 17-18.
  25. Tian, F. and Y. Xie, 2009. Research on implementation of DRGs payment system in TCM hospitals. Chinese Hospitals, 13: 16-18.
  26. Tian, F. and Y. Xie, 2009. Research on foreign countries' laws and regulations on surveillance and reporting of Post-marketing drugs adverse reactions. China J. Chin. Materia Med., 34: 1464-1466.
    PubMed  |